Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Because SGLT2 inhibitors act on the kidney, and the amount of glucose ... which showed a reduction in urinary glucose excretion of ~85% in T2DM patients with moderate to severe renal impairment ...

Urinary glucose excretion ... Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells ...

a sodium glucose co-transporter 2 (SGLT2) inhibitor. Dapagliflozin helps regulate blood sugar by promoting glucose excretion through urine, reducing reliance on insulin. This approach, paired with ...

Acute renal failure is caused by damage to the kidneys, which can occur as a result of blood loss, toxins, or physical damage to the kidneys. Acute renal failure occurs rapidly, causing generalized ...